- Home
- VIVS vs EDVA Comparison
VIVS vs EDVA Comparison
Compare VIVS & EDVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | EDVA |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.8M |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VIVS | EDVA |
|---|---|---|
| Price | $0.16 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 721.4K | 553.0K |
| Earning Date | 11-13-2026 | 11-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,603,000.00 | $73,066.00 |
| Revenue This Year | $228,144.28 | $24,377.87 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.82 | N/A |
| 52 Week Low | $0.14 | $0.13 |
| 52 Week High | $3.40 | $0.33 |
Technical Indicators
Market Signals| Indicator | VIVS | EDVA |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 42.70 |
| Support Level | N/A | $0.15 |
| Resistance Level | $0.30 | $0.18 |
| Average True Range (ATR) | 0.02 | 0.01 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 36.23 | 67.11 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
About EDVA Endovia Health Sciences Inc. Common Stock
Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.